Clinical Research Directory

Inclusion Criteria: * Age ≥ 18 years. * Histologically or cytologically confirmed metastatic non-small cell lung cancer (NSCLC) or colorectal cancer (CRC). * Presence of metastatic disease with extracranial oligoprogression, defined as progression in up to five (≤5) individual lesions on CT or PET/CT imaging, while other known disease sites remain stable or controlled. * Received at least one prior line of standard systemic anticancer therapy, including maintenance therapy, for metastatic disease. * All oligoprogressive lesions are technically feasible and considered safe for image-guided 125I seed implantation, as determined by the treating interventional team. * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. Adequate organ function to undergo interventional procedures and systemic therapy, per institutional standards. * Ability to understand and willingness to sign written informed consent. Exclusion Criteria: * Pregnancy or breastfeeding. * Leptomeningeal disease or diffuse central nervous system involvement. Uncontrolled infection or serious medical comorbidities that, in the investigator's judgment, would preclude safe participation or interventional procedures. * Prior radiotherapy or brachytherapy requiring re-irradiation to the same tumor location planned for 125I seed implantation. * Known bleeding diathesis or uncorrectable coagulation disorders contraindicating interventional procedures. * Any other condition that, in the investigator's judgment, would make the patient unsuitable for the study.